Back to Browse Journals » The Application of Clinical Genetics » Volume 5

The genetic basis of severe combined immunodeficiency and its variants

Authors Tasher D, Dalal I

Published Date August 2012 Volume 2012:5 Pages 67—80

DOI http://dx.doi.org/10.2147/TACG.S18693

Received 10 February 2012, Accepted 12 March 2012, Published 7 August 2012

Diana Tasher,1,2 Ilan Dalal1,2
1The Pediatric Infectious and Immunology Unit, E Wolfson Medical Center, Holon, Israel; 2The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract: Severe combined immunodeficiency (SCID) syndromes are characterized by a block in T lymphocyte differentiation that is variably associated with abnormal development of other lymphocyte lineages (B and/or natural killer [NK] cells), leading to death early in life unless treated urgently by hematopoietic stem cell transplant. SCID comprises genotypically and phenotypically heterogeneous conditions, of which the genetic basis for approximately 85% of the underlying immunologic defects have been recently elucidated. A major obstacle in deciphering the pathogenesis of SCID syndromes is that different mutations in a single gene may give rise to distinct clinical conditions and that a similar clinical phenotype can result from mutations in different genes. Mutation analysis is now an important component of the complete evaluation of a patient with SCID since it has a dramatic impact on many aspects of this potentially life-threatening disease such as genetic counseling, prenatal diagnosis, modalities of treatment, and, eventually, prognosis. Dr Robert Good, one of the founders of modern immunology, described the SCID syndrome as "experiments of nature." By understanding the cellular and genetic basis of these immunodeficiency diseases and, eventually, normal immunity, we optimize the "bedside to research laboratory and back again" approach to medicine.

Keywords: severe combined immune deficiency, molecular defects, lymphocytes

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Binding of plasma proteins to titanium dioxide nanotubes with different diameters

Kulkarni M, Flašker A, Lokar M, Mrak-Poljšak K, Mazare A, Artenjak A, Čučnik S, Kralj S, Velikonja A, Schmuki P, Kralj-Iglič V, Sodin-Semrl S, Iglič A

International Journal of Nanomedicine 2015, 10:1359-1373

Published Date: 18 February 2015

Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial

Checa MA, Brassesco M, Sastre M, Gómez M, Herrero J, Marque L, Brassesco A, Espinós JJ

International Journal of Women's Health 2015, 7:219-225

Published Date: 12 February 2015

Value of portal venous system radiological indices in predicting esophageal varices

Gaduputi V, Patel H, Sakam S, Neshangi S, Ahmed R, Lombino M, Chilimuri S

Clinical and Experimental Gastroenterology 2015, 8:89-93

Published Date: 9 February 2015

Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release

Manaia EB, Kaminski RCK, Oliveira AG, Corrêa MA, Chiavacci LA

International Journal of Nanomedicine 2015, 10:811-819

Published Date: 22 January 2015

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging

Verma VK, Kamaraju SR, Kancherla R, Kona LK, Beevi SS, Debnath T, Usha SP, Vadapalli R, Arbab AS, Chelluri LK

International Journal of Nanomedicine 2015, 10:711-726

Published Date: 20 January 2015

Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies

Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX

International Journal of Nanomedicine 2015, 10:633-644

Published Date: 14 January 2015

Using registries to identify type 2 diabetes patients

Thomsen RW, Sørensen HT

Clinical Epidemiology 2015, 7:1-3

Published Date: 18 December 2014